Scholarlink

Objective <p>[<sup>18</sup>F]SMBT-1 is a selective and reversible monoamine oxidase B (MAO-B) radiotracer used for astrogliosis imaging. This study aimed to observe the whole-body biodistribution of [¹⁸F]SMBT-1 and evaluate peripheral MAO-B expression in healthy human volunteers using dynamic positron emission tomography (PET) imaging.</p> Methods <p>Six healthy subjects (four males, two females; age range: 21–63 years) underwent nine dynamic PET scans over 5.5&#xa0;h after [<sup>18</sup>F]SMBT-1 injection. The first five emission scans were acquired consecutively in a single session within 30&#xa0;min (min) of post-injection (p.i.). The remaining four emission scans were performed at 70–110, 150–180, 220–250, and 290–330&#xa0;min p.i. Regions of interest (ROIs) were manually drawn on the co-registered PET and magnetic resonance imaging (MRI) for the selected organs to extract mean standardized uptake values (SUV<sub>mean</sub>) and generate time-activity curves (TACs).</p> Results <p>A significantly high early uptake of [<sup>18</sup>F]SMBT-1 was observed in the kidneys, liver, heart, and stomach between 5 and 30&#xa0;min p.i. The kidneys showed the highest early peak at 5&#xa0;min p.i. (SUV<sub>mean</sub> = 14.2 ± 3.5). The gallbladder and intestines exhibited a delayed uptake pattern, with the gallbladder SUV<sub>mean</sub> increasing substantially from 9.0 ± 4.2 at 30&#xa0;min to 123.7 ± 53.4 at 330&#xa0;min. No significant differences in tracer uptake patterns were observed across participants.</p> Conclusion <p>[¹⁸F]SMBT-1 exhibited favorable reversible kinetics in the whole-body biodistribution assessment, confirming its established utility for imaging reactive astrocytes and indicating its potential for future applications in systemic high MAO-B-related pathologies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Whole-body biodistribution of [18F]SMBT-1: a novel PET tracer for monoamine oxidase B imaging in healthy humans

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Berihu Mesfin,
  • Yui Ishioka,
  • Yoshiki Ichinose,
  • Akihito Inamura,
  • Yingying Wu,
  • Shoichi Watanuki,
  • Kotaro Hiraoka,
  • Yoshihito Funaki,
  • Asuka Kikuchi,
  • Kazuko Takeda,
  • Masayasu Miyake,
  • Ryuichi Harada,
  • Shozo Furumoto,
  • Nobuyuki Okamura,
  • Kazuhiko Yanai,
  • Hiroshi Watabe,
  • Manabu Tashiro

摘要

Objective

[18F]SMBT-1 is a selective and reversible monoamine oxidase B (MAO-B) radiotracer used for astrogliosis imaging. This study aimed to observe the whole-body biodistribution of [¹⁸F]SMBT-1 and evaluate peripheral MAO-B expression in healthy human volunteers using dynamic positron emission tomography (PET) imaging.

Methods

Six healthy subjects (four males, two females; age range: 21–63 years) underwent nine dynamic PET scans over 5.5 h after [18F]SMBT-1 injection. The first five emission scans were acquired consecutively in a single session within 30 min (min) of post-injection (p.i.). The remaining four emission scans were performed at 70–110, 150–180, 220–250, and 290–330 min p.i. Regions of interest (ROIs) were manually drawn on the co-registered PET and magnetic resonance imaging (MRI) for the selected organs to extract mean standardized uptake values (SUVmean) and generate time-activity curves (TACs).

Results

A significantly high early uptake of [18F]SMBT-1 was observed in the kidneys, liver, heart, and stomach between 5 and 30 min p.i. The kidneys showed the highest early peak at 5 min p.i. (SUVmean = 14.2 ± 3.5). The gallbladder and intestines exhibited a delayed uptake pattern, with the gallbladder SUVmean increasing substantially from 9.0 ± 4.2 at 30 min to 123.7 ± 53.4 at 330 min. No significant differences in tracer uptake patterns were observed across participants.

Conclusion

[¹⁸F]SMBT-1 exhibited favorable reversible kinetics in the whole-body biodistribution assessment, confirming its established utility for imaging reactive astrocytes and indicating its potential for future applications in systemic high MAO-B-related pathologies.